Literature DB >> 29802469

X chromosome gain is related to increased androgen receptor expression in male breast cancer.

Enrico Di Oto1, Giovanni B Biserni1, Zsuzsanna Varga2, Luca Morandi1, Maria C Cucchi3, Riccardo Masetti4, Maria P Foschini5.   

Abstract

X chromosome gain has been previously described in male breast cancer (MBC). Androgen receptor (AR) gene is located on X chromosome. The aim of this study was to investigate the role of the X chromosome gain in the development of MBC and its relation with AR gene copy number and expression.The X chromosome status was assessed in 66 cases of male invasive and in situ duct breast carcinoma, in 34 cases of gynecomastia associated with cancer, and in 11 cases of tumor-free gynecomastia. Cases were tested by fluorescence in situ hybridization (FISH) to assess the X chromosome status and AR amplification. AR expression was studied by immunohistochemistry (IHC). In addition, AR methylation status was assessed.X chromosome gain was observed in 74.7% of invasive duct carcinoma, in 20.6% of in situ duct carcinoma, and in 14.6% of gynecomastia when associated with cancer, while all cases of tumor-free gynecomastia showed wild X chromosome asset. AR gene copy number when increased paralleled the number of X chromosomes. AR IHC expression was observed in 100% of MBC tested. AR gene methylation status revealed low level or absence of methylation.These data suggest that X chromosome can play a role in the neoplastic transformation of male breast epithelium. X chromosome gain is paralleled by AR gene polysomy. Polysomic AR genes show low methylation levels and high AR protein expression on IHC. These data should be taken into consideration for MBC treatment planning.

Entities:  

Keywords:  Androgen receptor; FISH; Genetic marker; Invasive ductal carcinoma; Male breast cancer; X chromosome

Mesh:

Substances:

Year:  2018        PMID: 29802469     DOI: 10.1007/s00428-018-2377-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  29 in total

1.  Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Authors:  Shusma C Doebar; Leen Slaets; Fatima Cardoso; Sharon H Giordano; John Ms Bartlett; Konstantinos Tryfonidis; Nizet H Dijkstra; Caroline P Schröder; Christi J van Asperen; Barbro Linderholm; Kim Benstead; Winan Nm Dinjens; Ronald van Marion; Paul J van Diest; John Wm Martens; Carolien Hm van Deurzen
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.

Authors:  Antonio C Wolff; M Elizabeth Hammond; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2012-05-10       Impact factor: 13.506

3.  Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer.

Authors:  Maurizio Callari; Vera Cappelletti; Loris De Cecco; Valeria Musella; Patrizia Miodini; Silvia Veneroni; Manuela Gariboldi; Marco Alessandro Pierotti; Maria Grazia Daidone
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

4.  Tracing differences between male and female breast cancer: both diseases own a different biology.

Authors:  Robert Kornegoor; Paul J van Diest; Horst Buerger; Eberhard Korsching
Journal:  Histopathology       Date:  2015-06-26       Impact factor: 5.087

5.  Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series.

Authors:  Luigi Di Lauro; Patrizia Vici; Maddalena Barba; Laura Pizzuti; Domenico Sergi; Massimo Rinaldi; Anna Di Benedetto; Isabella Sperduti; Abeer M Shaaban; Valerie Speirs; Marcella Mottolese; Ruggero De Maria; Marcello Maugeri-Saccà
Journal:  Breast Cancer Res Treat       Date:  2014-09-20       Impact factor: 4.872

6.  Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Authors:  Marijn A Vermeulen; Leen Slaets; Fatima Cardoso; Sharon H Giordano; Konstantinos Tryfonidis; Paul J van Diest; Nizet H Dijkstra; Carolien P Schröder; Christi J van Asperen; Barbro Linderholm; Kim Benstead; Renee Foekens; John W M Martens; John M S Bartlett; Carolien H M van Deurzen
Journal:  Eur J Cancer       Date:  2017-03-11       Impact factor: 9.162

7.  Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism.

Authors:  C J Brown; S J Goss; D B Lubahn; D R Joseph; E M Wilson; F S French; H F Willard
Journal:  Am J Hum Genet       Date:  1989-02       Impact factor: 11.025

8.  Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study.

Authors:  Anthony J Swerdlow; Minouk J Schoemaker; Craig D Higgins; Alan F Wright; Patricia A Jacobs
Journal:  J Natl Cancer Inst       Date:  2005-08-17       Impact factor: 13.506

9.  Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy.

Authors:  Albrecht Röpke; Andreas Erbersdobler; Peter Hammerer; Jüri Palisaar; Kerstin John; Markus Stumm; Peter Wieacker
Journal:  Prostate       Date:  2004-04-01       Impact factor: 4.104

10.  Methylation plotter: a web tool for dynamic visualization of DNA methylation data.

Authors:  Izaskun Mallona; Anna Díez-Villanueva; Miguel A Peinado
Journal:  Source Code Biol Med       Date:  2014-06-07
View more
  2 in total

1.  Profile of Male Breast Cancer in Makkah Region of Saudi Arabia: A 4-Year Retrospective Analysis of Radiology and Histopathology.

Authors:  Muhammad Saeed; Bothaina Mohammed Abdulshakour; Najwa Abdalkabeer A Bantan; Afnan Hisham Falemban; Munir Abdulla; Ehab M Melibary; Ahmad H Mufti; Mohiuddin M Taher
Journal:  Int J Breast Cancer       Date:  2022-06-22

2.  Genomic and transcriptomic characterization of the human glioblastoma cell line AHOL1.

Authors:  W A S Ferreira; C K N Amorim; R R Burbano; R A R Villacis; F A Marchi; T S Medina; M M C de Lima; E H C de Oliveira
Journal:  Braz J Med Biol Res       Date:  2021-01-15       Impact factor: 2.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.